September 2023 Trans-Divisional Council-Approved Concepts

Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.

Note: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Fiscal Year (FY) 2025 Concepts

Center of Excellence for Systems Modeling of Infection and Immunity Across Biological Scales

For the published request for applications, check the March 13, 2024 Guide announcement, Center of Excellence for Systems Modeling of Infection and Immunity Across Biological Scales (U54 Clinical Trial Not Allowed). Also refer to the related notice of special interest published on July 23, 2024, Notice of Special Interest (NOSI): Systems Modeling of Infection and Immunity Across Biological Scales. 

U.S.-Brazil Collaborative Biomedical Research - Phase 2

Request for Applications—proposed FY 2025 initiative

Contact: 
Lucy Ruderman
lucy.ruderman@nih.gov
301-761-7896

Objectives:

  • To increase U.S. scientists’ access to infectious disease and immunology research opportunities in Brazil and support U.S. scientists’ funding for collaborative research projects.
  • To foster, expand, and strengthen U.S.-Brazil basic, clinical, and translational research collaboration.

Description: This initiative will support U.S. investigators working with Brazilian colleagues in collaborative research projects. An overall program of cooperation with Brazil, which will include this initiative, may also include separately supported workshops, training, and other jointly developed activities. The focus will be on immunology and infectious diseases, including HIV/AIDS and its comorbidities [additional areas of focus may be added by other participating NIH institutes and centers (ICs) including the National Cancer Institute, National Human Genome Research Institute, National Institute on Aging, National Institute of Child Health and Human Development, National Institute of Environmental Health Sciences, National Institute of Neurological Disorders and Stroke, National Institute of Mental Health, Office of AIDS Research, and other ICs]. Areas of priority interest to NIAID are determined by U.S. scientists and are likely to include HIV/AIDS, malaria, bacterial infections including tuberculosis, sexually transmitted infections, influenza, pandemic preparedness, neglected tropical diseases, parasitic diseases, antimicrobial resistance, arboviral infections, and adjuvant discovery and the role of immune responses in pathogenesis. Following standard NIH review and award practices, NIAID and the other participating ICs will fund U.S. co-investigators; the Brazil Ministry of Health (MS) and Ministry of Science, Technology, Innovation, and Communication (MCTI) will fund the Brazilian co-investigators through the National Council for Scientific and Technological Development (CNPq) in each joint research project application.

U.S.-South Africa Program for Collaborative Biomedical Research - Phase 3 (Infectious Diseases)

Request for Applications—proposed FY 2025 initiative

Contacts: 
Peter Gerstenberger
peter.gerstenberger@nih.gov
240-747-7157

Holly Curtis
holly.curtis@nih.gov
301-761-5666

Objectives:

  • To increase U.S. scientists’ access to infectious disease and immunology research opportunities in South Africa and support U.S. scientists’ funding for collaborative research projects.
  • To foster, expand, and strengthen U.S.-South Africa basic, clinical, and translational research collaboration.

Description: This initiative will support U.S. investigators working with South African colleagues in collaborative research projects focused on infectious disease and immunology research [non-HIV/AIDS]. An overall program of cooperation with South Africa, which will include this initiative, may also include separately supported workshops, training, and other jointly developed activities. The focus will be on immunology and infectious diseases, not including HIV/AIDS and sexually transmitted infections [additional areas of focus may be added by other participating NIH institutes and centers (ICs)]. Areas of priority interest to NIAID are determined by U.S. scientists and are likely to include malaria, tuberculosis, influenza, pandemic preparedness, parasitic diseases, antimicrobial resistance, arboviral infections, other viral diseases with pandemic potential, and adjuvant discovery and the role of immune responses in pathogenesis. Following standard NIH review and award practices, NIAID and the other participating ICs will fund U.S. co-investigators; the South Africa Medical Research Council will provide the funding for the South African co-investigators.

U.S.-South Africa Program for Collaborative Biomedical Research - Phase 3 (HIV/AIDS and STIs)

For the published request for applications, check the September 17, 2024 Guide announcement, U.S.-South Africa Program for Collaborative Biomedical Research - Phase 3 (HIV/AIDS) (R01, Clinical Trial Optional).

NIAID Clinical Trial Implementation Cooperative Agreement

For the published program announcement with special receipt, referral, and/or review considerations, check the January 29, 2024 Guide announcement, NIAID Clinical Trial Implementation Cooperative Agreement (U01, Clinical Trial Required).

NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement

For the published program announcement with special receipt, referral, and/or review considerations, check the January 29, 2024 Guide announcement, NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44, Clinical Trial Required).

Content last reviewed on